Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Atossa Therapeutics Inc ATOS

Healthcare Biotechnology
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company’s lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also... see more

Current News (NDAQ:ATOS)

Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium

PR Newswire December 15, 2025

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy

PR Newswire December 11, 2025

Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen

PR Newswire December 9, 2025

Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum

PR Newswire December 4, 2025

Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma

PR Newswire December 2, 2025

Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation

PR Newswire November 17, 2025

Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

PR Newswire November 12, 2025

Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium

PR Newswire November 6, 2025

Atossa Therapeutics Highlights Progress in RECAST(TM) DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents

PR Newswire October 21, 2025
View More News ››

Opinion & Analysis (NDAQ:ATOS)

Coverage initiated on developer of potential breast cancer therapy competitor

Streetwise Reports January 31, 2018
View More Opinion ››

Bullboard Posts (NDAQ:ATOS)

Excellent, YouTube analysis on Atossa!!

https://youtu.be/qDyE4zA02qU?si=lZUpAB1tA3HBbxli
BryceCanada - April 8, 2024

Dr Quay has issued a letter to shareholders.

It is worth reading as it provides an update on the recent activities of the company including its cash position.  B.
B8lair8 - February 4, 2023

Atossa has been moving well recently on ...

higher volume and higher share price. It's almost like somebody knows something.  
B8lair8 - January 18, 2023

anything?

.
thedave2006 - March 9, 2021

it's doing well today

keep holding it still,so glta.
coolfooldumbguy - March 26, 2019

RE:still holding this stock

Did it peak yesterday at 7.38? I'd be surprised if this stock doesn't hit 10 dollars today. GLTA 
daybehouse - March 15, 2019
View more Bullboard ››

Interactive Capital Partners Corporation

Interactive Capital Partners Corporation

View More »

Podcasts